
Opinion|Videos|August 15, 2023
CheckMate 9ER Trial Updates
Author(s)Rana R. McKay, MD
Centering discussion on the CheckMate 9ER trial, Dr. McKay shares perspective of recent follow-up data of nivolumab + cabozantinib in frontline advanced RCC.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















